Efficacy of Lenvatinib Therapy for Thyroid Cancer by Pathological Type: A Retrospective Real-world Study.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-09-01 DOI:10.21873/invivo.14085

Mioko Matsuo, Mamoru Ito, Kenji Tsuchihashi, Hirofumi Ohmura, Kazuki Hashimoto, Ryunosuke Kogo, Masanobu Sato, Shogo Masuda, Takashi Nakagawa

{"title":"Efficacy of Lenvatinib Therapy for Thyroid Cancer by Pathological Type: A Retrospective Real-world Study.","authors":"Mioko Matsuo, Mamoru Ito, Kenji Tsuchihashi, Hirofumi Ohmura, Kazuki Hashimoto, Ryunosuke Kogo, Masanobu Sato, Shogo Masuda, Takashi Nakagawa","doi":"10.21873/invivo.14085","DOIUrl":null,"url":null,"abstract":"Background/aim: Refractory differentiated thyroid carcinoma (DTC) and anaplastic thyroid carcinoma (ATC) are associated with poor prognoses. Molecularly targeted agents such as lenvatinib are expected to significantly improve outcomes. However, data from real-world settings remain limited.Patients and methods: A retrospective analysis was conducted in 48 patients with thyroid carcinoma treated with lenvatinib at Kyushu University Hospital between April 2015 and October 2024. We compared overall survival (from time of treatment initiation to death, censoring, or data cutoff) and progression-free survival (from time of treatment initiation to tumor progression as confirmed by image examination) using Kaplan-Meier analysis. A subgroup analysis was also conducted for patients who had and had not received prior radioactive iodine (RAI) therapy.Results: The analysis included 29 female and 19 male cases. The histologic types were papillary thyroid carcinoma in 26 patients, follicular thyroid carcinoma in seven patients, and ATC in 15 patients. Of 33 DTC cases, RAI was not administered in nine cases. The median progression-free survival was 30 months for papillary thyroid carcinoma, 18 months for follicular thyroid carcinoma, and four months for ATC. The median progression-free survival for patients with DTC who received RAI therapy was 19 months, whereas that for patients with DTC without RAI therapy was 46 months. No significant difference was found between the two groups (p=0.243).Conclusion: Lenvatinib may be effective in patients with DTC in whom RAI treatment is not feasible in real-world settings.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2854-2861"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396069/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14085","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Refractory differentiated thyroid carcinoma (DTC) and anaplastic thyroid carcinoma (ATC) are associated with poor prognoses. Molecularly targeted agents such as lenvatinib are expected to significantly improve outcomes. However, data from real-world settings remain limited.

Patients and methods: A retrospective analysis was conducted in 48 patients with thyroid carcinoma treated with lenvatinib at Kyushu University Hospital between April 2015 and October 2024. We compared overall survival (from time of treatment initiation to death, censoring, or data cutoff) and progression-free survival (from time of treatment initiation to tumor progression as confirmed by image examination) using Kaplan-Meier analysis. A subgroup analysis was also conducted for patients who had and had not received prior radioactive iodine (RAI) therapy.

Results: The analysis included 29 female and 19 male cases. The histologic types were papillary thyroid carcinoma in 26 patients, follicular thyroid carcinoma in seven patients, and ATC in 15 patients. Of 33 DTC cases, RAI was not administered in nine cases. The median progression-free survival was 30 months for papillary thyroid carcinoma, 18 months for follicular thyroid carcinoma, and four months for ATC. The median progression-free survival for patients with DTC who received RAI therapy was 19 months, whereas that for patients with DTC without RAI therapy was 46 months. No significant difference was found between the two groups (p=0.243).

Conclusion: Lenvatinib may be effective in patients with DTC in whom RAI treatment is not feasible in real-world settings.

Abstract Image

查看原文本刊更多论文

Lenvatinib治疗甲状腺癌病理类型的疗效：一项回顾性现实世界研究。

背景/目的：难治性分化甲状腺癌（DTC）和间变性甲状腺癌（ATC）与不良预后相关。分子靶向药物如lenvatinib有望显著改善预后。然而，来自真实世界的数据仍然有限。患者与方法：回顾性分析2015年4月至2024年10月在九州大学医院接受lenvatinib治疗的48例甲状腺癌患者。我们使用Kaplan-Meier分析比较了总生存期（从治疗开始到死亡、筛选或数据截止）和无进展生存期（从治疗开始到图像检查证实的肿瘤进展）。亚组分析还对先前接受和未接受放射性碘（RAI）治疗的患者进行了分析。结果：女性29例，男性19例。组织学类型为甲状腺乳头状癌26例，滤泡性甲状腺癌7例，ATC 15例。在33例DTC病例中，9例未给予RAI。甲状腺乳头状癌的中位无进展生存期为30个月，滤泡性甲状腺癌为18个月，ATC为4个月。接受RAI治疗的DTC患者的中位无进展生存期为19个月，而未接受RAI治疗的DTC患者的中位无进展生存期为46个月。两组间差异无统计学意义（p=0.243）。结论：Lenvatinib可能对在现实环境中无法进行RAI治疗的DTC患者有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.